Investigation of Cytomegalovirus Serology in Adult Individuals in Erzurum Region.

Year 2025, Volume: 35 Issue: 1, 104 - 109, 28.02.2025

Mahmut Ucar , Ahmet Yılmaz , Gürsel Bedir

https://doi.org/10.54005/geneltip.1536319

Abstract

Aims: Cytomegalovirus, a double-stranded DNA virus in the family Herpesviridae, like other known herpes viruses, remains latent throughout a person's life following the initial infection in CMV and causes recurrent infections. The aim of the study was to reveal the current status of CMV seroprevalence in adults in Erzurum and to investigate the trends in CMV infection by comparing the obtained seroprevalence data with the previously reported data.

Materials and Methods: In our study, the results of people whose anti-CMV IgG and anti-CMV IgM serology were investigated by family physicians in Erzurum between 2020-2023 were retrospectively analyzed. Blood samples of individuals were studied in Erzurum Public Health Serology Laboratory using the ELISA method using the Architect kit. In order to make comparisons between individuals, the working group; It was divided into 6 different age groups: 18-24, 25-29, 30,34, 35-39, 40-49 and ≥50.

Results: The population of our study consisted of 9,252 people between the ages of 18 and 103 who were investigated for anti-CMV IgG serology, and 13,276 people between the ages of 18 and 97 for anti-CMV IgG. Anti-CMV IgG seropositivity was 98.5% and anti-CMV IgM seropositivity was 2.1% in our study group. Anti-CMV IgG and IgM positivity were 98.7% and 2.1%, respectively, in women; 97.7% and 2.2% in men.

Conclusions: In our study, anti-CMV IgG seropositivity was found to be 98.7%, anti-CMV IgM seropositivity was found to be 2.1%, and CMV IgG seropositivity rates were found to be higher in our province compared to similar studies conducted in our country. The CMV IgM seropositivity rate is consistent with the data from Turkey.

Keywords

Cytomegalovirus, anti-CMV IgG, anti-CMV IgM, prevalence, Erzurum

Ethical Statement

I, as the author, by signing the below letter declare that: 1. The manuscript is original work of author(s). All data, tables, figures, etc. used in the manuscript are prepared originally by authors, otherwise the sources are cited and reprint permission is attached. 2. The manuscript has not been and will not be published elsewhere or submitted elsewhere for publication. 3. Authors mention that there is no conflict of interest in this study. 4. The paper, the final version of which I enclose, is not substantially the same as any that I/we have already published elsewhere. 5. No more changes in the authors or main results is accepted from my side after submitting to the journal. If you have any further question, be free to contact us. Thank you for your attention.

Supporting Institution

We did not receive any financial support for our research.

Thanks

The researchers would like to thank Savaş Calık, Public Health Laboratory Manager, and Hasan Kutan, Health Officer, for their contributions in obtaining the data used in the study.

Erzurum Bölgesinde Yetişkin Bireylerde Sitomegalovirüs Serolojisinin Araştırılması.

Abstract

Giriş: Herpesviridae ailesinde çift sarmallı bir DNA virüsü olan sitomegalovirüs bilinen diğer herpes virüsleri gibi CMV’de ilk enfeksiyonu takiben kişinin hayatı boyunca latent kalır ve tekrar eden enfeksiyonlara neden olur. Çalışmanın amacı, Erzurum’da yetişkin bireylerde CMV seroprevalansının güncel durumunu ortaya koymak ve elde edilen seroprevalans verilerin daha önce bildirilen verilerle karşılaştırarak CMV enfeksiyonundaki eğilimleri araştırmaktır.
Materyal method: Çalışmamızda 2020-2023 yılları arasında Erzurum’da aile hekimlerince anti-CMV IgG ve anti-CMV IgM serolojisi araştırılan kişilere ait sonuçlar retrospektif olarak incelendi. Kişilere ait kan örnekleri Erzurum Halk Sağlığı Seroloji Laboratuvarında ELISA yöntemiyle Architect kiti kullanılarak çalışılmıştı. Bireyler arasında kıyaslama yapabilmek için çalışma grubu; 18-24, 25-29, 30,34, 35-39, 40-49 ve ≥50 olmak üzere 6 farklı yaş grubuna bölündü.
Bulgular: Araştırmamızın evreni anti-CMV IgG serolojisi araştırılan 18 ve 103 yaş arasında 9.252 kişiden, anti-CMV IgM ise 18 ve 97 yaşları arasında 13.276 kişiden oluşmakta idi. Çalışma grubumuzda anti-CMV IgG seropozitifliği %98.5, anti-CMV IgM seropozitifliği ise %2.1 oranında bulundu. Anti-CMV IgG ve IgM pozitifliği kadınlarda sırasıyla %98.7, %2.1; erkeklerde ise %97.7, %2.2 oranında bulundu.
Sonuç: Araştırmamızda anti-CMV IgG seropozitifliği %98.7, anti-CMV IgM seropozitifliği %2.1 oranında bulunmuş olup, ülkemizde yapılan benzer çalışmalarla kıyaslandığında CMV IgG seropozitiflik oranları ilimizde daha yüksek bulunmuştur. CMV IgM seropozitiflik oranı ise Türkiye verileriyle uyumludur.

Keywords

Sitomegalovirüs, anti-CMV IgG, anti-CMV IgM, prevalans, Erzurum

References

• 1. Gorun F, Motoi S, Malita D, Navolan DB, Nemescu D, Olariu TR, et al. Cytomegalovirus seroprevalence in pregnant women in the western region of Romania: A large-scale study. Exp Ther Med 2020;20:2439-2443.
• 2. Fowler K, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Grys M, et al. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health 2022;22:1659.
• 3. Cannon MJ, Stowell JD, Clark R, Dollard PR, Johnson D, Mask K, et al. Repeated measures study of weekly and daily cytomegalovirus shedding patterns in saliva and urine of healthy cytomegalovirus-seropositive children. BMC Infect Dis 2014;14:1-10.
• 4. Revello MG, Campanini G, Piralla A, Furione M, Percivalle E, Zavattoni M, et al. Molecular epidemiology of primary human cytomegalovirus infection in pregnant women and their families. J Med Virol 2008;80:1415-1425.
• 5. Nolan N, Halai U-A, Regunath H, Smith L, Rojas-Moreno C, Salzer W. Primary cytomegalovirus infection in immunocompetent adults in the United States–A case series. IDCases 2017;10:123-126.
• 6. Hoehl S, Berger A, Ciesek S, Rabenau HF. Thirty years of CMV seroprevalence—a longitudinal analysis in a German university hospital. Eur J Clin Microbiol Infect Dis 2020;39:1095-1102.
• 7. Griffiths PD. The burden of disease associated with human cytomegalovirus and prospects for elimination by universal immunization. Lancet Infect Dis 2012;12:790-798.
• 8. Lancini D, Faddy HM, Flower R, Hogan C. Cytomegalovirus disease in immunocompetent adults. Med J Aust 2014;201:578-580.
• 9. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The “silent” global burden of congenital cytomegalovirus. Clin Microbiol Rev 2013;26:86-102.
• 10. Lachmann R, Loenenbach A, Waterboer T, Brenner N, Pawlita M, Michel A, et al. Cytomegalovirus (CMV) seroprevalence in the adult population of Germany. PloS one 2018;13:e0200267.
• 11. Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol 2010;20:202-213.
• 12. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis 2006;43:1143-1151.
• 13. Souza MA, Passos AM, Treitinger A, Spada C. Seroprevalence of cytomegalovirus antibodies in blood donors in southern Brazil. Rev Soc Bras Med Trop 2010;43:359-361.
• 14. Lopo S, Vinagre E, Palminha P, Paixão MT, Nogueira P, Freitas MG. Seroprevalence to cytomegalovirus in the Portuguese population, 2002-2003. Euro Survei 2011;16:19896.
• 15. Vilibic-Cavlek T, Kolaric B, Beader N, Vrtar I, Tabain I, Mlinaric-Galinovic G. Seroepidemiology of cytomegalovirus infections in Croatia. Wien Klin Wochenschr 2017;129:129-135.
• 16. Olsson J, Kok E, Adolfsson R, Lövheim H, Elgh F. Herpes virus seroepidemiology in the adult Swedish population. Immu Ageing 2017;14:1-6.
• 17. Choi SR, Kim K-R, Kim DS, Kang J-M, Kim SJ, Kim JM, et al. Changes in cytomegalovirus seroprevalence in Korea for 21 years: a single center study. Pediatric Infection & Vaccine. 2018;25:123-131.
• 18. Aljumaili ZKM, Alsamarai AM, Najem WS. Cytomegalovirus seroprevalence in women with bad obstetric history in Kirkuk, Iraq. J Infect Public Health 2014;7:277-288.
• 19. Rahimzadeh G, Safar MJ, Rezai S, Rezai MS, Movahedi FS. Seroepidemiology of HBV, HCV, HIV, HTLV, and CMV in pregnant women referring to Sari Birth Cohort. Adv Biomed Res 2022;11:97.
• 20. Das A, Munian D, Maity C, Pandey S, Paul S, Bhattacharya P. Prevalence of cytomegalovirus infections in blood donors and the newborn versus utility of leukocyte-reduced blood transfusion in the premature newborn: an observation from Eastern India. Journal of Clinical Neonatology 2023;12:65-71.
• 21. Mahallawi W, Khabour OF, Al-Saedi A, Almuzaini Z, Ibrahim N. Human Cytomegalovirus Seroprevalence Among Blood Donors in the Madinah Region, Saudi Arabia. Cureus 2022;14:e21860.
• 22. Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta‐analysis. Rev Med Virol 2019;29:e2034.
• 23. Ataman S, Colak D, Guenseren F, Senol Y, Colak T, Aktekin MR, et al. Investigation of cytomegalovirus seroepidemiology in Antalya with a population-based cross-sectional study and review of related data in Turkey. Mikrobiyol Bul 2007;414:545-555.
• 24. Demir E, Dinç HÖ, Özbey D, Akkuş S, Ergin S, Kocazeybek BS. Retrospective Evaluation of Toxoplasma gondii, Rubella and Cytomegalovirus Seropositivity and Avidity Test Results in patients admitted to İU-C Cerrahpaşa Medical Faculty Hospital Between 2013-2018. Turk Mikrobiyol Cemiy Derg 2020;50:35-43.
• 25. Akpınar O, Akpınar H. Gebe Investigation Of The Rubella And Cytomegalovirus Seroprevalences By Elisa Method In Pregnant Women. Balıkesir Sağlık Bilimleri Dergisi 2017;6:11-15.
• 26. Bakacak M, Bostancı MS, Köstü B, Ercan Ö, Serin S, Avcı F, et al. Seroprevalance of Toxoplasma gondii, rubella and cytomegalovirus among pregnant women. Dicle Med J 2014;41:326-331.
• 27. Petersen MR, Patel EU, Abraham AG, Quinn TC, Tobian AA. Changes in cytomegalovirus seroprevalence among US children aged 1–5 years: the national health and nutrition examination surveys. Clin Infect Dis 2021;72:e408-e411.
• 28. Tiguman GMB, Poll LB, Alves CEdC, Pontes GS, Silva MT, Galvao TF. Seroprevalence of cytomegalovirus and its coinfection with Epstein-Barr virus in adult residents from Manaus: a population-based study. Rev Soc Brasil Med Trop 2020;53:e20190363.
• 29. Antona D, Lepoutre A, Fonteneau L, Baudon C, Halftermeyer-Zhou F, Le Strat Y, et al. Seroprevalence of cytomegalovirus infection in France in 2010. Epidemiol Infect 2017;145:1471-1478.
• 30. Billette de Villemeur A, Tattevin P, Salmi L-R. Hygiene promotion might be better than serological screening to deal with Cytomegalovirus infection during pregnancy: a methodological appraisal and decision analysis. BMC Infect Dis 2020;20:1-15.
• 31. Winter JR, Taylor GS, Thomas OG, Jackson C, Lewis JE, Stagg HR. Factors associated with cytomegalovirus serostatus in young people in England: a cross-sectional study. BMC Infect Dis 2020;20:1-9.
• 32. van Zuylen WJ, Zheng QY, Hamilton ST, Egilmezer EE, Craig ME, Gralton J, et al. Prevalence of cytomegalovirus carriage among childcare staff. J Paediatr Child Health 2017;53:724.
• 33. Wujcicka W, Gaj Z, Wilczyński J, Sobala W, Śpiewak E, Nowakowska D. Impact of socioeconomic risk factors on the seroprevalence of cytomegalovirus infections in a cohort of pregnant Polish women between 2010 and 2011. Eur J Clin Microbiol Infect Dis 2014;33:1951-1958.
• 34. Bernstein DI. Congenital cytomegalovirus: a “now” problem no really, now. Clin and Vaccine Immunol 2017;24: e00491-16.
• 35. Enders G, Daiminger A, Lindemann L, Knotek F, Bäder U, Exler S, et al. Cytomegalovirus (CMV) seroprevalence in pregnant women, bone marrow donors and adolescents in Germany, 1996–2010. Med Microbiol Immunol 2012;201:303-309.
• 36. Takemoto K, Nishimura N, Kozawa K, Hibino H, Kawaguchi M, Takeuchi S, et al. Time-series analysis comparing the prevalence of antibodies against nine viral species found in umbilical cord blood in Japan. Jpn J Infect Dis 2016;69:314-318.
• 37. Madendağ Y, Eraslan Şahin M, Çöl Madendağ İ, Şahin E, G. A. Investigation of toxoplasma, cytomegalovirus and rubella seroprevalence in pregnant women admitted to our hospital. Perinatoloji Dergisi 2018;26:7-10.
• 38. Çubuk F, Hasbek M, Kafa AHT, Çelik C. Evaluation of Serological Indicators for Toxoplasma, Rubella Virus and Cytomegalovirus Infections in Pregnant Women Applied to Our Hospital. Türk Mikrobiyoloji Cemiy Derg 2020;50:211-217.
• 39. Lazzarotto T, Guerra B, Gabrielli L, Lanari M, Landini MP. Update on the prevention, diagnosis and management of cytomegalovirus infection during pregnancy. Clini Microbiol Infect 2011;17:1285-1293.